These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 31722893)
21. Obstacles to early treatment of idiopathic pulmonary fibrosis: current perspectives. Moua T; Ryu JH Ther Clin Risk Manag; 2019; 15():73-81. PubMed ID: 30655671 [TBL] [Abstract][Full Text] [Related]
22. Dual inhibition of α Decaris ML; Schaub JR; Chen C; Cha J; Lee GG; Rexhepaj M; Ho SS; Rao V; Marlow MM; Kotak P; Budi EH; Hooi L; Wu J; Fridlib M; Martin SP; Huang S; Chen M; Muñoz M; Hom TF; Wolters PJ; Desai TJ; Rock F; Leftheris K; Morgans DJ; Lepist EI; Andre P; Lefebvre EA; Turner SM Respir Res; 2021 Oct; 22(1):265. PubMed ID: 34666752 [TBL] [Abstract][Full Text] [Related]
23. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases. Lamb YN Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296 [TBL] [Abstract][Full Text] [Related]
24. "Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD". Ariel A. Calderon, Colin Dimond, David F. Choy, Rajita Pappu, Michele A. Grimbaldeston, Divya Mohan and Kian Fan Chung. Eur Respir Rev; 2023 Jun; 32(168):. PubMed ID: 37019459 [No Abstract] [Full Text] [Related]
25. Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study. Adams CJ; Shapera S; Ryerson CJ; Assayag D; Johannson KA; Fell CD; Morisset J; Manganas H; Kolb M; Hambly N; Cox G; Khalil N; Marcoux V; Wilcox PG; To T; Sadatsafavi M; Halayko AJ; Gershon A; Garlick K; Fisher JH Respir Med; 2022 Jan; 191():106722. PubMed ID: 34959146 [TBL] [Abstract][Full Text] [Related]
26. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Oku H; Shimizu T; Kawabata T; Nagira M; Hikita I; Ueyama A; Matsushima S; Torii M; Arimura A Eur J Pharmacol; 2008 Aug; 590(1-3):400-8. PubMed ID: 18598692 [TBL] [Abstract][Full Text] [Related]
27. Antifibrotic Therapy: Is There a Role in Myositis-Interstitial Lung Disease? Soskis A; Hallowell R Respiration; 2021; 100(9):923-932. PubMed ID: 33951665 [TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis. Aono Y; Nakamura Y; Kono M; Nakamura H; Yokomura K; Imokawa S; Toyoshima M; Yasui H; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Suda T Ther Adv Respir Dis; 2020; 14():1753466620953783. PubMed ID: 32928050 [TBL] [Abstract][Full Text] [Related]
29. Clinical Overview of Progressive Fibrotic Interstitial Lung Disease. Case AH Front Med (Lausanne); 2022; 9():858339. PubMed ID: 35372405 [TBL] [Abstract][Full Text] [Related]
30. Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Ghazipura M; Mammen MJ; Herman DD; Hon SM; Bissell BD; Macrea M; Kheir F; Khor YH; Knight SL; Raghu G; Wilson KC; Hossain T Ann Am Thorac Soc; 2022 Jun; 19(6):1040-1049. PubMed ID: 35499854 [No Abstract] [Full Text] [Related]
31. The antifibrotic effects and mechanisms of microRNA-26a action in idiopathic pulmonary fibrosis. Liang H; Xu C; Pan Z; Zhang Y; Xu Z; Chen Y; Li T; Li X; Liu Y; Huangfu L; Lu Y; Zhang Z; Yang B; Gitau S; Lu Y; Shan H; Du Z Mol Ther; 2014 Jun; 22(6):1122-1133. PubMed ID: 24594795 [TBL] [Abstract][Full Text] [Related]
32. Management of patients with fibrosing interstitial lung diseases. Morrow LE; Hilleman D; Malesker MA Am J Health Syst Pharm; 2022 Jan; 79(3):129-139. PubMed ID: 34608488 [TBL] [Abstract][Full Text] [Related]
33. Characteristic patterns in the fibrotic lung. Comparing idiopathic pulmonary fibrosis with chronic lung allograft dysfunction. Fernandez IE; Heinzelmann K; Verleden S; Eickelberg O Ann Am Thorac Soc; 2015 Mar; 12 Suppl 1():S34-41. PubMed ID: 25830833 [TBL] [Abstract][Full Text] [Related]
34. Diagnosis and Management of Fibrotic Interstitial Lung Diseases. Collins BF; Luppi F Clin Chest Med; 2021 Jun; 42(2):321-335. PubMed ID: 34024407 [TBL] [Abstract][Full Text] [Related]
35. Targeting the angiotensin pathway in idiopathic pulmonary fibrosis. Antoniu SA Expert Opin Ther Targets; 2008 Dec; 12(12):1587-90. PubMed ID: 19007325 [TBL] [Abstract][Full Text] [Related]
36. "Cardiovascular disease and COPD: dangerous liaisons." Klaus F. Rabe, John R. Hurst and Samy Suissa. Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30463874 [No Abstract] [Full Text] [Related]
37. Improvement of the pharmacokinetics and antifibrotic effects of nintedanib by intrapulmonary administration of a nintedanib-hydroxypropyl-γ-cyclodextrin inclusion complex in mice with bleomycin-induced pulmonary fibrosis. Togami K; Ogasawara A; Irie S; Iwata K; Yamaguchi K; Tada H; Chono S Eur J Pharm Biopharm; 2022 Mar; 172():203-212. PubMed ID: 35183716 [TBL] [Abstract][Full Text] [Related]